Sugi Predict

Sugi Predict / Compounds / SCHEMBL4021269

SCHEMBL4021269

SCHEMBL4021269

CC(C)(O)CNc1cc(Oc2ccc(F)cc2F)nc2[nH]nc(-c3cc(F)ccc3F)c12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK14 Q16539 6/20 0.42
▸ MET P08581 2/20 0.36
▸ AXL P30530 2/20 0.36
▸ TYRO3 Q06418 2/20 0.36
▸ MERTK Q12866 2/20 0.36
▸ LPAR2 Q9HBW0 2/20 0.35
▸ BRD4 O60885 4/20 0.34
▸ MAP4K4 O95819 3/20 0.34
▸ MAPK9 P45984 3/20 0.34
▸ CSNK1A1 P48729 3/20 0.34
▸ CSNK1D P48730 3/20 0.34
▸ MINK1 Q8N4C8 3/20 0.34
▸ MAP4K5 Q9Y4K4 2/20 0.34
▸ PRKD2 Q9BZL6 1/20 0.34
▸ PRKD3 O94806 2/20 0.33
▸ CSNK1G3 Q9Y6M4 2/20 0.33
▸ FGFR1 P11362 1/20 0.33
▸ FRK P42685 1/20 0.33
▸ MAPK8 P45983 1/20 0.33
▸ GSK3B P49841 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4016857 0.84 MAPK14 (0.40) MAPK14METAXLTYRO3MERTK
SCHEMBL4016081 0.83 MAPK14 (0.42) MAPK14METAXLTYRO3MERTK
SCHEMBL4018020 0.82 MAPK14 (0.39) MAPK14METAXLTYRO3MERTK
SCHEMBL4833006 0.76 MAPK14 (0.43) MAPK14METAXLTYRO3MERTK
SCHEMBL4841320 0.76 MAPK14 (0.41) MAPK14METAXLTYRO3MERTK
SCHEMBL4832917 0.75 MAPK14 (0.40) MAPK14METAXLTYRO3MERTK
SCHEMBL4015286 0.75 MAPK14 (0.35) MAPK14METAXLTYRO3MERTK
SCHEMBL4015293 0.75 MAPK14 (0.35) MAPK14METAXLTYRO3MERTK
SCHEMBL4021724 0.75 MAPK14 (0.39) MAPK14METAXLTYRO3MERTK
SCHEMBL4838097 0.75 MAPK14 (0.43) MAPK14METAXLTYRO3MERTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1919470-A1 FUSED PYRAZOLE AS p38 MAP KINASE INHIBITORS F.HOFFMANN-LA ROCHE AG (CH) 2008-05-14 — — EP claimed
US-20070203160-A1 p38 MAP kinase inhibitors and methods for using the same ROCHE PALO ALTO LLC 2007-08-30 — — US claimed
WO-2007023105-A1 FUSED PYRAZOLE AS p38 MAP KINASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2007-03-01 — — WO claimed
US-7566708-B2 Substituted pyrazolo{3,4-D}pyrimidines as p38 map kinase inhibitors ROCHE PALO ALTO LLC (US) 2009-07-28 — — US disclosed
US-7566708-B2 Substituted pyrazolo{3,4-D}pyrimidines as p38 map kinase inhibitors ROCHE PALO ALTO LLC (US) 2009-07-28 — — US disclosed
US-7566708-B2 Substituted pyrazolo{3,4-D}pyrimidines as p38 map kinase inhibitors ROCHE PALO ALTO LLC (US) 2009-07-28 — — US disclosed
EP-1919470-A1 FUSED PYRAZOLE AS p38 MAP KINASE INHIBITORS F.HOFFMANN-LA ROCHE AG (CH) 2008-05-14 — — EP disclosed
US-20070203160-A1 p38 MAP kinase inhibitors and methods for using the same ROCHE PALO ALTO LLC 2007-08-30 — — US disclosed
US-20070203160-A1 p38 MAP kinase inhibitors and methods for using the same ROCHE PALO ALTO LLC 2007-08-30 — — US disclosed
US-20070203160-A1 p38 MAP kinase inhibitors and methods for using the same ROCHE PALO ALTO LLC 2007-08-30 — — US disclosed
WO-2007023105-A1 FUSED PYRAZOLE AS p38 MAP KINASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2007-03-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070203160-A1 p38 MAP kinase inhibitors and methods for using the same MAPKAPK2, MAPK1, MAP3K2 MAPK14 33/4885MET 1428/4885AXL 3403/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.